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ﬁ ndings as a randomised controlled 
trial.4 Although Heinonen and 
colleagues’ results are in line with 
our trial data and might support 
changing vaccination guidelines for 
young children, cost-eﬀ ectiveness 
analysis incorporating seasons with 
vaccine mismatching and statistical 
uncertainty in eﬃ  cacy estimates needs 
to be done to further convince health 
politicians and the public. 
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Inﬂ uenza vaccination in 
young children
Santtu Heinonen and colleagues1 
recorded substantial reductions in 
conﬁ rmed symptomatic episodes 
of inﬂ uenza in young children who 
received inactivated inﬂ uenza vaccine 
with both a non-randomised cohort 
and case-control design. The case-
control design was applied to quantify 
any potential selection bias. However, 
the main discussion in the discipline 
currently focuses on potential 
confounding by risk factors because of 
diﬀ erential selection for vaccination in 
non-randomised studies.2 
Average age, for example, diﬀ ered 
greatly between vaccinated and 
unvaccinated groups, which will bias 
the eﬀ ect estimates from the null. 
The applied stratiﬁ ed analyses for 
age can eﬀ ectively control such bias. 
However, parental smoking behaviour 
and day care attendance were also 
diﬀ erent between groups, though 
not statistically signiﬁ cant, and other 
potential confounders were not 
reported or measured. 
Therefore, results from an earlier 
randomised controlled trial among 
children from the Netherlands might 
be useful.3 In that trial, 579 children 
aged 18–72 months were randomly 
allocated to receive two doses of 
parenteral inactivated trivalent sub-
unit inﬂ uenza vaccine and placebo, 
inﬂ uenza vaccine and heptavalent 
pneumococcal conjugate vaccine, 
or control recombinant hepatitis B 
vaccine and placebo. During inﬂ uenza 
seasons, nose-throat swabs were PCR 
positive for inﬂ uenza virus in 4% (12 of 
271) of children in the ﬁ rst group and 
in 5% (11 of 243) of children in the 
second group. In the control group, 
the incidence was doubled (9%, 25 of 
270) and the eﬃ  cacy was estimated in 
both vaccination arms to be around 
50% (lower bound 95% CI 3). 
These data show that a carefully 
conducted non-randomised cohort 
study can produce much the same 
is poor and often does not provide 
seroprotection in the ﬁ rst 3 years of 
life.2,3 On the basis of this notion, even 
when the circulating B strain perfectly 
matches that included in the vaccine, 
this vaccine is not an ideal means of 
protecting young children against 
inﬂ uenza, especially when substantial 
B-strain circulation is expected. 
Because more immunogenic and 
eﬀ ective vaccines than that used 
by Heinonen and colleagues will 
probably be approved for children in 
the near future, we believe that the 
investigators’ recommendation to 
use trivalent inactivated inﬂ uenza 
vaccine in children aged 9 months 
to 3 years should be less categorical, 
and that their discussion should have 
considered data for the new vaccines. 
Vesikari and colleagues3 compared a 
trivalent inactivated inﬂ uenza vaccine 
and an MF59-adjuvanted vaccine, 
and found that MF59 signiﬁ cantly 
improved immunogenicity against 
the B vaccine virus and led to greater 
than 90% seroprotection rates 
against matched strains in all children 
irrespective of age. Moreover, a study 
of the MF59-adjuvanted vaccine in 
children aged between 6 months 
and 6 years4 showed clinical eﬃ  cacy 
rates of 89% against disease caused 
by vaccine-matched strains and 
86% against all circulating strains, 
which are signiﬁ cantly higher than 
the 45% and 43% eﬃ  cacy of trivalent 
inactivated inﬂ uenza vaccine reported 
by Heinonen and colleagues. Live 
attenuated inﬂ uenza vaccine has 
an eﬃ  cacy of 86% against B strains 
of the same lineage, 55% against 
antigenically drifted strains of the 
same lineage, and 31% against strains 
of the opposite B lineage that were 
antigenically unrelated to the vaccine 
strain.5
Finally, Heinonen and colleagues 
recorded no adverse events. Trivalent 
inactivated inﬂ uenza vaccine is well 
tolerated, but adverse events occurred 
in all the other studies and this makes 
us question whether the assessment 
was made correctly. 
The results of the investigation by 
Santtu Heinonen and colleagues1 
into the eﬀ ectiveness of a trivalent 
inactivated inﬂ uenza vaccine in 
children aged 9 months to 3 years 
can lead to diﬀ erent conclusions than 
those drawn by the authors. 
The results show that trivalent 
inactivated inﬂ uenza vaccine is not 
eﬀ ective against inﬂ uenza B infection, 
irrespective of age. This ﬁ nding (which 
was only reported in the discussion) 
is attributed to the lineage-level 
mismatch between the circulating 
B strain and that included in the 
vaccine, but could have been expected 
because several studies have shown 
that the antibody response induced 
by trivalent inactivated inﬂ uenza 
vaccine against inﬂ uenza B viruses 
